Last updated: July 31, 2026
Sodium benzoate and sodium phenylacetate are the active ingredients in Ammonul, an intravenous nitrogen-scavenging therapy for acute hyperammonemia caused by urea-cycle disorders. The product addresses a rare, emergency-care market rather than a broad chronic-treatment segment. Its active ingredients are established, inexpensive small molecules with limited apparent patent protection. Commercial value rests mainly on regulatory approval, hospital availability, manufacturing reliability, emergency-use protocols and physician familiarity.
The near-term market outlook is stable to modestly growing. Demand is tied to diagnosis of urea-cycle disorders, neonatal intensive-care capacity, metabolic-disease centers and continued use during acute decompensation. Growth is constrained by the small patient population, competition from dialysis and alternative nitrogen scavengers, and the availability of oral maintenance therapies such as glycerol phenylbutyrate and sodium phenylbutyrate.
What is sodium benzoate and sodium phenylacetate used for?
Sodium benzoate and sodium phenylacetate are administered intravenously to reduce ammonia concentrations in patients with acute hyperammonemia caused by deficiencies in urea-cycle enzymes. Ammonul is used with dietary protein restriction and, when clinically indicated, hemodialysis or peritoneal dialysis.
The two compounds remove nitrogen through alternative pathways:
- Sodium phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted in urine.
- Sodium benzoate conjugates with glycine to form hippuric acid, which is also excreted in urine.
- Each pathway removes nitrogen without requiring the defective urea-cycle step.
The FDA label identifies Ammonul as an adjunctive treatment for acute hyperammonemia in patients with deficiencies of carbamoyl phosphate synthetase, ornithine transcarbamylase, argininosuccinate synthetase, argininosuccinate lyase, arginase and related urea-cycle functions (U.S. Food and Drug Administration [FDA], 2018).
What is the FDA regulatory status of Ammonul?
Ammonul is an FDA-approved prescription product administered by intravenous infusion. It is supplied as a concentrated solution containing sodium phenylacetate and sodium benzoate in a 10% dextrose vehicle. The product requires dilution before administration and carries important risks involving sodium load, metabolic disturbances, neurotoxicity and infusion-related complications.
The approved indication is acute hyperammonemia, not routine chronic prevention. Treatment protocols generally combine Ammonul with:
- Immediate discontinuation of protein intake.
- Intravenous glucose and adequate caloric support.
- Arginine supplementation when indicated.
- Serial ammonia monitoring.
- Hemodialysis or continuous renal replacement therapy for severe or refractory cases.
The product is used primarily in metabolic intensive-care settings, neonatal intensive-care units, emergency departments and specialized pediatric hospitals.
What clinical trials support sodium benzoate and sodium phenylacetate?
The clinical evidence base is older and narrower than the evidence supporting newer chronic nitrogen-scavenging drugs. Sodium phenylacetate and sodium benzoate entered practice through studies of nitrogen metabolism, emergency treatment of hyperammonemia and clinical experience in urea-cycle disorders rather than through a modern, large randomized development program.
What do clinical studies show about efficacy?
Clinical studies and treatment series support rapid ammonia reduction when sodium phenylacetate and sodium benzoate are administered with glucose, arginine and dialysis when required. Evidence is strongest for biochemical ammonia control and acute metabolic rescue. Studies were generally limited by the rarity of urea-cycle disorders, heterogeneous patient ages, varying disease severity and the ethical difficulty of withholding treatment during life-threatening crises.
The principal clinical endpoints have been:
- Change in plasma ammonia.
- Time to ammonia normalization or clinically acceptable reduction.
- Survival from metabolic crisis.
- Neurologic recovery.
- Avoidance or duration of dialysis.
- Adverse events linked to sodium burden and phenylacetate exposure.
The treatment is not a cure for the underlying enzyme defect. Neurologic outcomes depend heavily on the duration and severity of hyperammonemia before treatment begins.
What is the current clinical-trial pipeline?
No major late-stage trial program is associated with the fixed intravenous combination itself. Current clinical development in urea-cycle disorders is concentrated in:
- Oral nitrogen scavengers for maintenance therapy.
- Gene therapy and mRNA approaches targeting specific enzyme deficiencies.
- Improved newborn screening and earlier diagnosis.
- Biomarkers that predict metabolic crises.
- Dialysis and intensive-care protocols.
ClinicalTrials.gov lists studies involving urea-cycle disorders, hyperammonemia and alternative nitrogen-scavenging products, but the combination of sodium benzoate and sodium phenylacetate is generally used as established rescue therapy rather than as an investigational intervention (National Library of Medicine, n.d.).
How does the treatment compare with alternative nitrogen scavengers?
| Therapy |
Route |
Primary role |
Market position |
| Sodium phenylacetate plus sodium benzoate |
Intravenous |
Acute hyperammonemia |
Emergency and intensive-care use |
| Sodium phenylbutyrate |
Oral |
Chronic nitrogen control |
Established maintenance treatment |
| Glycerol phenylbutyrate |
Oral liquid |
Chronic maintenance treatment |
Premium chronic therapy |
| Sodium benzoate alone |
Oral or compounded |
Adjunctive nitrogen scavenging |
Variable use by center and jurisdiction |
| Hemodialysis or continuous renal replacement therapy |
Extracorporeal |
Rapid ammonia removal |
Rescue for severe or refractory cases |
| Arginine and citrulline |
Intravenous or oral |
Urea-cycle pathway support |
Adjunctive treatment |
Glycerol phenylbutyrate and sodium phenylbutyrate generate phenylacetate after metabolism and are more suitable for long-term management. Ammonul remains differentiated by intravenous delivery and immediate use during metabolic crisis.
What patents protect sodium benzoate and sodium phenylacetate?
The active ingredients are old, well-characterized chemical compounds. The core composition is unlikely to support meaningful new-molecule patent protection. Any historic patents covering the active ingredients or basic use would generally have expired.
The remaining intellectual-property opportunities are more likely to involve:
- Formulation stability.
- Container and dilution systems.
- Ready-to-use infusion presentations.
- Manufacturing and impurity-control methods.
- Dosing algorithms.
- Combination protocols.
- Diagnostic selection of patients at risk of hyperammonemia.
How strong is the patent estate for Ammonul?
The patent estate appears weak relative to newer specialty drugs. Ammonul’s commercial protection is primarily regulatory and operational rather than patent-based.
| IP category |
Assessment |
| Composition of matter |
Weak or expired |
| Basic method of treating hyperammonemia |
Likely expired or difficult to enforce |
| Intravenous formulation |
Potentially narrow and vulnerable |
| Manufacturing process |
Potentially relevant but difficult to detect from public product information |
| Device or container |
Possible, but commercially limited |
| Method-of-use claims |
Limited scope because the indication and mechanism are established |
| Orphan exclusivity |
Historic protection may have applied, but any original period would have ended |
| Biosimilar protection |
Not applicable |
No biosimilar pathway applies because sodium benzoate and sodium phenylacetate are small-molecule active ingredients. A competing product would generally be evaluated as a generic drug or another 505(b)(2) product, depending on its formulation, clinical reliance and labeling strategy.
What is the Orange Book status of sodium benzoate and sodium phenylacetate?
Ammonul is an approved small-molecule drug product, but its market protection should not be analyzed like a recently approved branded medicine. The relevant questions are whether the reference product has unexpired listed patents, whether regulatory exclusivity remains, and whether a prospective applicant can obtain approval using an abbreviated pathway.
The practical Orange Book risk profile is:
- No meaningful new chemical entity exclusivity remains.
- Any original orphan-drug exclusivity would have expired.
- The active ingredients themselves are not commercially difficult to synthesize.
- A generic applicant could focus on pharmaceutical equivalence, concentration, sterility, container closure and labeling.
- Formulation differences could push an applicant toward a 505(b)(2) strategy.
The FDA Orange Book remains the controlling source for current patent-listing and exclusivity information. A listed patent would matter only if it remains unexpired and covers the proposed generic product or its approved use (FDA, n.d.-a).
When does sodium benzoate and sodium phenylacetate lose exclusivity?
The core chemical and clinical exclusivity for sodium benzoate and sodium phenylacetate has already lapsed. The key commercial exposure is therefore generic entry rather than a future loss of branded exclusivity.
A generic launch could occur through several routes:
| Launch pathway |
Likely commercial effect |
| Therapeutically equivalent injectable generic |
Direct price pressure and hospital formulary substitution |
| 505(b)(2) reformulation |
Potential differentiation through ready-to-use packaging or stability |
| Compounded sodium benzoate or sodium phenylacetate |
Limited substitution, subject to state and federal compounding rules |
| Hospital or specialty distributor sourcing |
Greater supply-chain competition |
| Alternative oral nitrogen scavenger |
Substitution mainly in chronic care, not acute rescue |
The principal barrier is not patent expiration. It is the small market, sterile manufacturing requirements, limited demand predictability and the need for uninterrupted supply during emergencies.
Which companies are challenging the Ammonul market?
Competition is fragmented rather than concentrated. Relevant competitors include manufacturers of oral nitrogen scavengers, suppliers of compounded products, hospitals with metabolic-care protocols and manufacturers of dialysis equipment.
What companies sell competing nitrogen-scavenging therapies?
Bausch Health and related specialty-pharmaceutical operations have commercial exposure to urea-cycle-disorder therapies, including products associated with sodium phenylbutyrate and glycerol phenylbutyrate. Horizon Therapeutics, acquired by Amgen, commercialized Buphenyl and Ravicti before the acquisition. Other market participants may supply generic, compounded or regionally distributed products.
The competitive landscape is divided into two segments:
- Acute rescue: Ammonul, dialysis, arginine, glucose and intensive-care support.
- Chronic control: Ravicti, Buphenyl, sodium benzoate, dietary management and emerging genetic therapies.
Direct substitution between these segments is limited. Oral products cannot fully replace intravenous emergency treatment in a patient with severe hyperammonemia who cannot tolerate oral or enteral administration.
What litigation and settlement agreements affect sodium benzoate and sodium phenylacetate?
The commercial record does not indicate a major, market-defining patent litigation campaign comparable with litigation surrounding high-revenue branded medicines. The old chemistry, orphan-disease market and limited expected generic revenue reduce the incentive for extensive Paragraph IV litigation.
Potential disputes would more likely concern:
- Whether a generic injectable is therapeutically equivalent.
- Sterility and container-closure compliance.
- Labeling for acute hyperammonemia.
- Manufacturing deviations or shortages.
- Product liability involving sodium load, dosing or infusion errors.
- Contractual supply arrangements.
No major public settlement agreement is central to the current market outlook. Any Paragraph IV filing would be commercially meaningful only if it solved the sterile-manufacturing and supply-scale problem.
What generic entry risks exist for Ammonul?
Generic entry risk is real but gradual. The product has characteristics that can delay competition despite weak patent protection:
- The indication is rare and episodic.
- Hospitals require dependable emergency inventory.
- Injectable products require validated sterile manufacturing.
- Demand is concentrated in specialist centers.
- A shortage can create reputational and regulatory risk for a new supplier.
- The reference product may have limited public sales data, reducing the attractiveness of development.
A successful generic could reduce acquisition cost for hospitals and Medicaid programs. The incumbent could retain share through supply reliability, emergency-stock contracts, clinician familiarity and distributor relationships.
What is the market size for sodium benzoate and sodium phenylacetate?
Public companies generally do not report Ammonul revenue separately. Market estimates must therefore be constructed from epidemiology, treatment frequency, hospital utilization and price assumptions rather than from audited segment disclosures.
Urea-cycle disorders are rare inherited metabolic diseases. Published estimates commonly place combined prevalence in the range of approximately one in 35,000 to one in 80,000 live births, although estimates vary by disorder, population and screening method (Häberle et al., 2019).
The addressable market is larger than the diagnosed patient population because Ammonul is stocked for emergency use and may be administered to patients whose final diagnosis is not yet confirmed.
What is the projected market value?
A reasonable planning range for the global branded and generic intravenous sodium phenylacetate/sodium benzoate market is approximately $30 million to $75 million annually, with the United States representing the largest commercial market. This is a market-sizing range, not reported manufacturer revenue.
| Scenario |
2024 estimated market |
2030 projected market |
2024-2030 CAGR |
Key assumptions |
| Low |
$25 million |
$28 million |
2% |
Generic pressure and stable diagnosis |
| Base |
$45 million |
$58 million |
4% |
More diagnosed patients and stable hospital pricing |
| High |
$70 million |
$100 million |
6% |
Increased screening, broader emergency stocking and limited competition |
The base case assumes that volume grows faster than patient prevalence because of improved recognition and earlier emergency treatment. Price growth remains constrained by the prospect of generic entry and payer scrutiny.
What drives future demand for the combination?
Demand is most sensitive to five variables:
- Newborn screening and genetic diagnosis.
- Survival of patients with severe urea-cycle disorders into adulthood.
- Number of metabolic centers and intensive-care units stocking the product.
- Availability and affordability of oral maintenance therapies.
- Frequency and severity of hyperammonemic crises.
Gene therapies could reduce long-term disease burden for selected patients, but they are unlikely to eliminate near-term demand for emergency ammonia control. Patients undergoing gene therapy, patients with incomplete response and undiagnosed patients may continue to require rescue treatment.
What manufacturing and geographic barriers affect the market?
The active ingredients are readily available chemicals, but the finished drug requires sterile injectable production, validated aseptic processing, quality testing and dependable distribution. Sodium content and concentration create formulation and labeling requirements that increase operational complexity.
The United States is the most commercially attractive market because of specialized metabolic centers, established FDA approval and high hospital reimbursement. Europe and other jurisdictions have demand but may rely more heavily on named-patient access, hospital compounding or locally authorized alternatives.
Geographic expansion depends on:
- National marketing authorization.
- Local reimbursement.
- Hospital procurement contracts.
- Emergency-stock requirements.
- Availability of metabolic specialists.
- Regulatory acceptance of the formulation and concentration.
How does sodium benzoate and sodium phenylacetate compare with newer therapies?
Ammonul has a narrow but defensible clinical role. Its strongest advantages are rapid intravenous administration and established use during acute metabolic crisis. Its weaknesses include sodium burden, infusion complexity, toxicity concerns and lack of suitability for chronic therapy.
| Attribute |
Ammonul |
Ravicti |
Buphenyl |
Gene therapy |
| Acute crisis use |
Strong |
Limited |
Limited |
Not established as rescue |
| Chronic use |
Poor fit |
Strong |
Strong |
Potentially disease-modifying |
| Route |
Intravenous |
Oral liquid |
Oral tablets or powder |
Intravenous or specialized administration |
| Patent position |
Weak |
Stronger historic product protection |
Largely mature |
Potentially strong |
| Price level |
Hospital emergency pricing |
High chronic-therapy pricing |
Lower than Ravicti in some markets |
Potentially very high |
| Main risk |
Sodium and phenylacetate toxicity |
Cost and adherence |
Taste, pill burden and adherence |
Efficacy, durability and safety |
What is the investment outlook for sodium benzoate and sodium phenylacetate?
The product is unlikely to become a large growth asset. Its value is more consistent with a niche hospital product that can generate durable revenue if supply remains reliable and competition stays limited.
The most attractive commercial strategies are:
- Secure sterile manufacturing capacity.
- Develop a ready-to-use or lower-burden infusion presentation.
- Obtain approvals in additional jurisdictions.
- Build hospital emergency-stock contracts.
- Pair acute therapy with chronic urea-cycle-disorder products.
- Acquire or license complementary metabolic-disease assets.
The main downside risks are generic injectable entry, manufacturing interruption, reimbursement reductions, declining use after improved diagnosis or disease-modifying therapies, and substitution by dialysis or alternative emergency protocols.
Key Takeaways
- Sodium benzoate and sodium phenylacetate are established intravenous nitrogen scavengers used for acute hyperammonemia.
- Ammonul is the principal reference product associated with the combination.
- Clinical evidence supports biochemical ammonia reduction and emergency metabolic management, but the trial base is small and largely historical.
- No significant late-stage trial program is focused on the fixed combination.
- Core composition and use patents are not likely to provide current protection.
- Biosimilar risk does not apply; generic injectable and 505(b)(2) competition are the relevant threats.
- The market is small, specialized and operationally protected by sterile manufacturing and emergency supply requirements.
- A reasonable global market range is about $30 million to $75 million annually, with a base-case 2030 value near $58 million.
- Chronic oral nitrogen scavengers and emerging gene therapies are the main adjacent competitive technologies.
- Commercial performance will depend more on supply reliability and hospital access than on patent exclusivity.
FAQs
Is sodium phenylacetate the same as sodium phenylbutyrate?
No. Sodium phenylbutyrate is an oral prodrug that is metabolized to phenylacetate. Sodium phenylacetate is administered directly, principally by intravenous infusion during acute hyperammonemia.
Can sodium benzoate and sodium phenylacetate be used for chronic treatment?
The combination is primarily an acute-care therapy. Chronic management usually uses oral nitrogen scavengers, dietary protein control and disease-specific supplementation.
Does Ammonul have biosimilar competition?
No. Biosimilar regulation applies to biological products. Ammonul contains small-molecule active ingredients, so competing products would generally follow generic or 505(b)(2) pathways.
What is the main clinical risk of Ammonul?
Major risks include sodium overload, electrolyte abnormalities, metabolic acidosis or alkalosis, neurologic toxicity from phenylacetate exposure and complications caused by delayed treatment or inadequate dialysis.
Could gene therapy eliminate the sodium benzoate and sodium phenylacetate market?
Gene therapy could reduce recurrent crises in successfully treated patients with selected urea-cycle defects. It is unlikely to eliminate near-term demand because diagnosis may occur during crisis, treatment response may vary and patients may still require emergency ammonia-lowering therapy.
References
-
Häberle, J., Burlina, A., Chakrapani, A., Dixon, M., Karall, D., Lindner, M., ... MacDonald, A. (2019). Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet Journal of Rare Diseases, 14, 32. https://doi.org/10.1186/s13023-019-1010-5
-
National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (2018). Ammonul (sodium phenylacetate and sodium benzoate) injection prescribing information. https://www.accessdata.fda.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
